Canakinumab treatment increases the 6MWT maximum and PFWD versus placebo. Patients were treated monthly with 150 mg canakinumab or placebo sc. MWD (A) and PFWD (B) were assessed at baseline and after 1, 2, 3, 6, 9, and 12 months of treatment. LS means (80% CI) of change from baseline in pain-free 6MWT distance are presented.
LS, least-squares; MWD, maximum walking distance; PFWD, pain-free walking distance; sc, subcutaneously; 6MWT, 6-minute walk test.
*p < 0.05 vs placebo.